Skip to content

Multi-omics integration and functional validation identify thrombospondin-1 as a functionally relevant mediator of doramectin-associated inhibition of glioblastoma migration and invasion.

Aug 2026 · International Journal of Biological Macromolecules · pp. 154154 · 0 citations · 56 references
Medicine

TL;DR

RNA sequencing of DRM-treated versus control rat C6 glioma cells identified 3747 differentially expressed genes, including 1660 upregulated and 2087 downregulated genes, with thrombospondin-1 markedly downregulated after DRM treatment, which may contribute to the anti-invasive effects of DRM.

Abstract

Glioblastoma (GBM) exhibits highly infiltrative growth that limits therapeutic efficacy and promotes recurrence. Although doramectin (DRM) has been shown to induce apoptosis and autophagy in GBM cells, its effects on tumor migration and invasion remain unclear. We performed integrative transcriptomic and functional analyses to identify mediators associated with DRM anti-invasive activity. RNA sequencing of DRM-treated versus control rat C6 glioma cells identified 3747 differentially expressed genes, including 1660 upregulated and 2087 downregulated genes, with thrombospondin-1 (THBS1) markedly downregulated after DRM treatment (log2 fold change = -5.9). These genes were mainly associated with extracellular matrix organization, focal adhesion, phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling, and migration-related pathways. Public single-cell, spatial transcriptomic, and pan-cancer analyses provided contextual evidence of heterogeneous expression across tumor cellular and spatial contexts and is associated with tumor-related functional states. Under matched 24 h conditions, 5-20 μM DRM dose-dependently suppressed glioma cell adhesion, wound closure, migration, and invasion, with 20 μM DRM reducing Transwell migration and invasion by approximately 82-93% relative to the corresponding 0 μM control group. THBS1 knockdown reduced migration and invasion, whereas THBS1 overexpression partially restored migration and invasion under DRM treatment; these effects were accompanied by changes in matrix metalloproteinase 2 and matrix metalloproteinase 9 (MMP2 and MMP9) expression and focal adhesion kinase (FAK)/Akt phosphorylation. Collectively, THBS1 is functionally associated with GBM invasive phenotypes and may contribute to the anti-invasive effects of DRM, with extracellular matrix remodeling and FAK/Akt-related phosphorylation changes representing plausible associated processes.

View source

Similar papers

Open access Jul 2026

NTMT1 (METTL11A) promotes MYC-dependent proliferation and downstream HLA-A suppression in cervical cancer

Findings identify NTMT1 as a candidate regulatory node associated with MYC activation and downstream HLA-A suppression, warranting further mechanistic and in-vivo investigation, and highlighting NTMT1 as a promising candidate for future therapeutic investigation.

Jin-Ling Zhang, Chen Chen, Huibin Song et al. · 0 citations
Open access Jul 2026

Unraveling the role of PPFIA1 in cancer: a comprehensive multi-omics analysis and functional validation from pan-cancer to pancreatic cancer

PPFIA1 emerges as a pan-cancer biomarker with prognostic significance and shows an oncogenic role in PAAD, potentially associating with EMT-related malignant phenotypes and warrants further investigation as a candidate biomarker and potential functional target for precision oncology.

Shu Li, Hailin Jiang, Xiaojia Li et al. · 0 citations
Open access Jul 2026

FZD5 drives macrophage-mediated immunomodulation and predicts prognosis in glioma: evidence from single-cell sequencing

FZD5 is a TAM-enriched marker in glioma tissues and a potential regulator of macrophage-associated immunosuppressive programs, supporting its utility as a prognostic biomarker and a candidate target for microenvironment-oriented interventions in glioma.

Jiong-Yuan Pei, Chen Huang, Chan-Tian Jiang et al. · 0 citations
Jul 2026

Integrative multi-omics profiling reveals DRG1 promotes hepatocellular carcinoma via c-Myc phosphorylation and facilitates lenvatinib resistance.

The findings identify DRG1 as a potential prognostic biomarker and therapeutic target in HCC and identify its underlying regulatory mechanisms as a potential strategy to improve lenvatinib response.

Peng Wang, Jun-Ying Xu, Hao Huang et al. · 0 citations
Open access Aug 2026

Transcriptomic Profiling of Adhesion GPCRs in Pancreatic Adenocarcinoma Identifies ADGRG7 and ADGRF1 as Novel Diagnostic Biomarkers and Therapeutic Targets

A highly distinct aGPCR dysregulation signature characterized by the massive upregulation of ADGRG7 and ADGRF1 is identified within the PAAD microenvironment, highlighting them as promising diagnostic biomarkers and actionable therapeutic targets for overcoming TME-mediated immunosuppression.

A. A. Khan, Sung-Gook Cho · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.